Linkedbio is the newly launched services provided by Lingmed. We help companies to understand and monitor China market opportunities, define the right strategies and work with the right partners

  • Linkedbio Partnering:

    Lingmed analyst team evaluates the innovative biotech products, technologies and medical devices to estimate the market size, risk & opportunities, to identify the right partner for the asset. Lingmed team will arrange partnering meetings to facilitate the direct dialogues, suggest deal structure to support deal closing

  • Linkedbio Analysis:

    Lingmed analyst team conducts desk researches and interviews to get insights on China market, we provide tailored product China market sizing analysis, deal valuation and competitive landscape reports to our clients

Latest Lingmed asset recommendation
Japanese Innovative Oncology Project——Treating HRD Positive Cancers Seeking partner in Greater China (LMP2823) (Tuesday, 19 May 2026)
  • Project ID: LMP2823
  • Company ID: LMC5001786
  • Project Description：Highly selective oral CDK12/13 inhibitors (RNA transcription elongation inhibitors)
  • Indications：HRD (Homologous Recombination Deficiency) positive cancers (triple-negative breast cancer, BRCA-mutated tumors) and CDK12-loss prostate cancer
  • Development Stage, Mode of Administration, Partnering Needs, Company Description, Project Highlights......
Related asset recommendations
European Innovative Pain Management Project —— Treating Neuropathic Pain Seeking partner in Greater China (LMP2818)
European Innovative Cardiac Surgery Implant Device Seeking partner in Greater China (LMP2817)
Latest Lingmed monthly webinar
Analysis of drug targets and key pharmaceutical companies in pain therapeutic area, are you ready? (Thursday, 14 Nov 2024)
Event details
  • Potential innovative targets for new pain drugs
  • Breakthroughs and innovations of non-addictive pain drugs
  • Competition landscape of the top 10 domestic companies in pain therapeutic area
  • An innovative biotech roadshow
Related monthly webinars
Application of nano-antibodies in autoimmune diseases, are you ready?
Breakthroughs & progress of antiepileptic drugs, are you ready?
General information
Product > 460
Company > 835
Deals > 391
Reports > 195
Non-confi PDF > 284